NCT07803198

Brief Summary

This study aims to investigate serum Asprosin concentrations in patients with BD and their relationship with disease activity and major clinical manifestations.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for all trials

Timeline
13mo left

Started Sep 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Sep 2026Oct 2027

First Submitted

Initial submission to the registry

August 31, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

September 1, 2026

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 3, 2026

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2027

Last Updated

September 3, 2026

Status Verified

August 1, 2026

Enrollment Period

1.1 years

First QC Date

August 31, 2026

Last Update Submit

August 31, 2026

Conditions

Behcet Disease

Outcome Measures

Primary Outcomes (2)

  • Assessment of asprosin level in behcet disease and its association with disease activity

    To investigate serum asprosin level in behcet disease

    Baseline

  • Assessment of asprosin level in behcet disease and its association with disease activity

    To investigate serum Asprosin concentrations in patients with BD.

    Baseline assessment at the time of enrollment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include adult patients with Behçet's disease fulfilling the International Criteria for Behçet's Disease (ICBD), as well as age- and sex-matched healthy controls. Patients will be recruited from the Rheumatology Department. The study will assess serum Asprosin levels in relation to disease activity in Behçet's disease.

You may qualify if:

  • Adult subjects (≥ 18 years) satisfying the International Criteria for Behçet's Disease (ICBD) will be included in \[7\].

You may not qualify if:

  • Patients with other autoimmune diseases.
  • Patients with Acute inflammatory condition at the time of blood sampling.
  • Pregnant participants, and participants with active infection, known malignancy, diabetes mellitus, chronic kidney or liver disease, thyroid or other endocrine disorders, obesity.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Behcet Syndrome

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesUveitis, AnteriorPanuveitisUveitisUveal DiseasesEye DiseasesVasculitisVascular DiseasesCardiovascular DiseasesHereditary Autoinflammatory DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin Diseases, GeneticSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Vascular

Study Officials

  • Marwa Ahmed Abdel- aziz Galal, MD

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Eman Ahmed Ibrahim

CONTACT

01155359235eymanahmad159@gmail.com

Samar Hasanein Goma, MD

CONTACT

01061828586

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

August 31, 2026

First Posted

September 3, 2026

Study Start

September 1, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

October 30, 2027

Last Updated

September 3, 2026

Record last verified: 2026-08